No Picture
News

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference

EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in … […]

No Picture
News

4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting

EMERYVILLE, Calif., Oct. 10, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced interim safety and clinical activity… […]

No Picture
News

4D Molecular Therapeutics to Participate in Chardan’s 5th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in… […]

No Picture
News

4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting

EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced a late-breaking presentation of pre… […]

No Picture
News

4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights

EMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the second q… […]

No Picture
News

4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights

EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the first qua… […]

No Picture
News

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

EMERYVILLE, Calif., May 12, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced new preclinical data from non-human p… […]

No Picture
News

4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform

EMERYVILLE, Calif., May 04, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced a new collaboration with investigator… […]

No Picture
News

4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference

EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will present at the… […]